Research Article

A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Rhizoma Dioscoreae Nipponicae in the Treatment of Asthma

Weiyi Wang 1, Liying Xu 2, Lingming Zhou 3, Shanhong Wan 3, and Libin Jiang 1

1 Department of Respiratory Medicine, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China
2 Department of Emergency, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, Zhejiang, China
3 Department of Respiratory Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

Correspondence should be addressed to Libin Jiang; jlb2020@sina.com

Received 7 May 2021; Accepted 23 February 2022; Published 30 March 2022

Academic Editor: Mozaniel Oliveira

Copyright © 2022 Weiyi Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. In this study, network pharmacological methods were used to analyze the targets of Rhizoma Dioscoreae Nipponicae (RDN) and investigate the potential underlying mechanism of RDN in the treatment of asthma. Methods. Asthma-related targets were obtained from the GeneCards and DisGeNET databases. The bioactive components of RDN were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform database, and the targets of these compounds were predicted using the BATMAN-TCM database. The network of RDN component targets was constructed using Cytoscape. A protein-protein interaction (PPI) network was constructed in Cytoscape to determine the potential targets of RDN for the treatment of asthma. The hub genes of RDN in the treatment of asthma were screened using network topological parameters. Gene ontology (GO) and the KEGG pathways were analyzed. Molecular docking and in vivo experiments were performed to validate the network pharmacology results. Results. A total of four bioactive components and 55 targets were identified. The results of the enrichment analysis suggested that the treatment of asthma with RDN involved signaling pathways, such as those related to systemic lupus erythematosus, alcoholism, viral carcinogenesis, the cell cycle, prostate cancer, transcriptional misregulation in cancer, hepatitis B, thyroid hormone signaling, and PI3K-AKT signaling, as well as other signaling pathways. Molecular docking showed that the active components of RDN could stably bind to the predicted target. In vivo experiments showed that RDN could regulate the expression of target genes and inhibit the activation of the PI3K-AKT signaling pathway. Conclusion. To a certain extent, this study reveals the potential bioactive components and molecular mechanisms of RDN in the treatment of asthma and provides new insights for the development of new drugs for asthma.

1. Introduction

Asthma is a common chronic condition characterized by chronic airway inflammation, which leads to increased bronchial hyperresponsiveness and mucus hypersecretion [1]. Asthma can be caused by a variety of stimuli, including viral infections, exposure to allergens and/or pollutants, smoking, sudden temperature variations, stress, and exercise [2, 3]. The global incidence of asthma was 43.12 million cases/year in 2017, with asthma incidence and mortality rates of 272.68 million and 490,000 cases, respectively, in the same year [4]. Asthma has a definite impact on the national economies of countries worldwide [5]. Presently, some patients with asthma cannot be effectively treated with corticosteroids. Therefore, it is necessary to develop new and significant treatments for asthma. Clinical studies have found that traditional Chinese medicine (TCM), a type of alternative medicine, has good clinical effects on asthma [6–8]. As a supplementary medicine, TCM is widely used in the treatment of asthma with good results and few side effects [9].
Rhizoma Dioscoreae Nipponicae (RDN) (ChuanShanlong) is indicated in many medical books and has various physiological effects, such as clearing heat, decreasing phlegm, relieving cough and asthma, dispersing blood stasis, and relieving pain [10]. Several findings have shown that RDN alleviates rheumatoid arthritis, treats hyperuricemia, improves thyroiditis, and relieves pulmonary fibrosis [11–14]. Moreover, our previous studies showed that RDN exhibited therapeutic effects in mice with chronic asthma [15–18]. However, the mechanisms of RDN in asthma treatment remain unclear.

TCM can act on multiple biological processes through multiple targets and bioactive components to treat diseases. Network pharmacology is a branch of pharmacology that is based on systems biology and multiple pharmacology theories and primarily focuses on biomolecular networks [19]. At present, network pharmacology is widely used in TCM research to reveal the mechanisms of complex herbal formulae by discovering bioactive ingredients and biomarkers. Furthermore, molecular docking is an important process in structural molecular biology and in computer-aided drug design for the development of new medicines [20].

Here, we analyzed the role of RDN in asthma treatment using a network pharmacology approach, and the results were validated by molecular docking and in vivo experiments.

2. Materials and Methods

2.1. Screening and Obtaining the Bioactive Components and Targets of RDN. In this study, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, https://lsp.hkbu.edu.hk/LSP/tcmsp.php) was used to determine the components of RDN [21]. TCM is mostly administered orally and exerts a variety of biological effects through its action on organs and tissues after absorption, distribution, metabolism, and excretion (ADME) in vivo, known as the pharmacokinetics of TCM. Oral bioavailability (OB) and drug-like (DL) are important parameters of ADME [22–24]. Components with OB ≥ 30% and DL ≥ 0.18 were selected as the main candidate bioactive components. In addition, more active components of RDN with significant pharmacological effects were supplemented based on previous studies [25].

BATMAN-TCM [26] was used to retrieve and predict the targets of the main bioactive components in RDN. In addition, components without potential targets were excluded. The targets were collected with a score cutoff of ≥40. The obtained targets, including the name, gene ID, and organism, were confirmed using the UniProt protein database (https://www.uniprot.org) [27]. The duplicate targets were removed and then uploaded to the Cytoscape platform to construct the herb-component-target network.

2.2. Identification of Asthma-Related Targets. The keyword “asthma” was used as the search term to collect disease targets based on the GeneCards (https://www.gene_cards.org) [28] and DisGeNET (https://www.disgenet.org) [29] databases.

The asthma-related targets obtained from the last search were uploaded to the STRING database (https://string-db.org) to analyze the relational value and were then imported to the Cytoscape platform to construct the asthma target network.

2.3. Construction of the Protein-Protein Interaction (PPI) Network. A PPI network was constructed and visually analyzed using the Cytoscape plugin BisoGenet, which contains six PPI databases: IntAct Molecular Interaction Database (IntAct), Biomolecular Interaction Network Database (BIND), Biological General Repository for Interaction Datasets (BioGRID), Database of Interacting Proteins (DIP), Molecular INTeraction Database (MINT), and Human Protein Reference Database (HPRD) [30]. PPI networks of RDN targets and asthma-related targets were constructed using Cytoscape.

Central network evaluation is considered a primary method for screening core proteins in PPI networks. First, the PPI networks of RDN targets and asthma-related targets were merged into an intersection. Next, the Cytoscape plugin CytoNCA was applied to assess the intersection from the six centrality measures: betweenness centrality (BC), closeness centrality (CC), degree centrality (DC), eigenvector centrality (EC), network centrality (NC), and the local average connectivity-based method (LAC) [31]. In addition, CytoHubba, a Cytoscape plugin, was used to select the hub genes [32].

2.4. GO and KEGG Pathway Enrichment Analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were carried out using the DAVID Bioinformatics Resources 6.8 database. GO analysis included three aspects: molecular function (MF), cellular component (CC), and biological process (BP).

2.5. Chemical Analysis of RDN. The RDN test sample was prepared according to a previous study [33]. Standard diosgenin was purchased from the Tauto Biological Technology Company (China). The chemical constituents of RDN were determined using an Agilent 1260 high-performance liquid chromatography (HPLC) system (Agilent, CA, USA). Samples (10 μL) were separated using an Agilent ZORBAX Eclipse Plus C18 column (4.6 mm × 250 mm, 5 μm) at 30°C, with mobile phases consisting of water (A) and acetonitrile (B). The following gradient conditions were used: 0–5 min, 15% B; 5–30 min, 15–40% B; and 30–50 min, 40–50% B. The flow rate was 1.0 mL/min, and the detection wavelength was 203 nm. Chromatograms are shown in Supplementary Figure 1. The retention time of diosgenin was 7.439 min.

2.6. Molecular Docking Analysis. The chemical structures of the RDN ingredients were downloaded from the ZINC website (https://zinc15.docking.org) [34], and three-dimensional structures of the hub genes were downloaded.
from the RCSB Protein Data Bank (PDB, https://www.pdb.org/) [35]. AutoDockTools (v1.5.6) and PyMol (v2.3.0) were used to remove water molecules, add polar hydrogen, and redistribute charge. Molecular docking was performed using AutoDock Vina (v1.1.2) and visualized using PyMol (v2.3.0).

2.7. Asthma Model Establishment and Treatment. Female BALB/c mice (6–8 weeks old, Shanghai SIPPR-BK Laboratory Animal Co. Ltd., China) were housed in a specific pathogen-free environment with a 12-h light-dark cycle, temperature of 23±2°C, and had free access to water and food. All animal experiments were approved by the Ethics Committee of Animal Experiments of the First Affiliated Hospital of Zhejiang Chinese Medical University.

After one week, mice were randomly divided into six groups (n = 6): control group, model group, model + RDN group, model + AKT agonist group, model + AKT agonist + RDN group, and model + prednisone acetate (PA) group. Mice were challenged by intraperitoneal injection of 0.2 ml of saline solution containing 50 μg of ovalbumin (grade V, Sigma-Aldrich, MO, USA) and 0.8 mg of aluminum hydroxide (Sigma-Aldrich) on days 0–3 and day 14. On day 14, day 17, day 20, day 23, and day 27, mice in the control group received inhaled phosphate-buffered saline using an ultrasonic nebulizer (402AL, Yuyue Medical Equipment Co. Ltd., China) for 20 min each time, and the rest of the mice received inhaled 2% ovalbumin solution. On days 14–27, mice in the model, model + RDN, model + AKT agonist (SC79, Sigma-Aldrich), model + AKT agonist + RDN, and model + PA (Sigma-Aldrich) groups were challenged with ovalbumin and were administered RDN (5 mg/kg administered by gavage), AKT agonist (10 mg/kg intraperitoneally), PA (5 mg/kg administered by gavage), or AKT agonist + RDN. Mice in the control group were challenged with phosphate-buffered saline.

2.8. Hematoxylin and Eosin (H&E) Staining. The lung tissues were collected and infused with 4% paraformaldehyde and were then dehydrated, paraffin-embedded, and cut into 5-μm-thick sections. The sections were then stained with hematoxylin for 3 min and eosin for 3 min. Finally, the pathological morphology of the mouse lung tissue was observed using a digital camera (Leica Microsystems Inc., IL, USA).

2.9. Quantitative Real-Time PCR (qRT-PCR) Analysis. Total RNA was extracted from lung tissues using TRIzol® Reagent (Invitrogen, CA, USA) and reverse transcribed into cDNA using the PrimeScript™ RT Reagent Kit (Takara, Japan). qRT-PCR was performed on a 7500 Real-Time PCR System (ThermoFisher Scientific, MD, USA) at 95°C for 3 min, 40 cycles of 95°C for 12 s, and 62°C for 40 s. The primers used are listed in Supplementary Table 1. The relative expression of genes was calculated using the 2^−ΔΔCT method, and GAPDH was used as an internal control.

2.10. Western Blotting. Total proteins were extracted using RIPA lysis buffer (Beyotime, China), separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to polyvinylidene fluoride membranes. The membranes were blocked with 5% skim milk for 1 h and incubated with the primary antibodies (1:1000, Abcam Co., MA, USA) at 4°C overnight and then incubated with the secondary antibodies at room temperature for 1 h. Finally, enhanced chemiluminescent reagents (FDbio, China) were used to visualize the protein bands.

2.11. Statistical Analysis. Data are presented as the means with standard deviation and were analyzed using SPSS 27.0. The differences between the groups were analyzed by one-way ANOVA, followed by Tukey’s test. Differences were considered statistically significant at p < 0.05.

3. Results

3.1. The Compound-Target Network of RDN. Two components of RDN were obtained from the TCMSP database. Studies have shown that 7-epitaxol and deoxyvasicinone are the major bioactive and principal toxic compounds of RDN. Therefore, 7-epitaxol and deoxyvasicinone were considered as the candidate components in this study. Collectively, we identified a total of 4 bioactive compounds and 55 targets for RDN, the details of which are shown in Tables 1 and 2. We subsequently constructed a compound-target network of RDN using Cytoscape (Figure 1).

3.2. GO and KEGG Pathway Enrichment Analyses of RDN. To further investigate the 55 targets of RDN, GO enrichment analysis was performed using GO terms from the BP, CC, and MF categories. The resultant targets of RDN were classified into 130 BP terms, 27 CC terms, and 31 MF terms, according to p < 0.01. The GO analysis results with the top 10 markedly enriched BP, CC, and MF terms are shown in Figures 2(a)–2(c). KEGG pathway enrichment analysis showed that the targets of the components in RDN were enriched in 12 associated pathways (p < 0.01). The top 10 KEGG pathways in which the targets of RDN were enriched are presented in Figures 2(d) and Table 3.

3.3. The Network of Asthma-Related Targets. The occurrence and development of asthma involve the co-regulation of multiple genes. Investigation of gene and gene-environment interactions is beneficial for elucidating the pathogenesis of asthma. In this study, 55 asthma-related targets were obtained from human genomic databases. The number of these targets in the GeneCards and DisGeNET databases was 19 and 38, respectively. These targets are detailed in Table 4.

3.4. The PPI Network of RDN and Asthma. The PPI networks of RDN and asthma were constructed using BisoGenet. The asthma-related target network was constructed with 1,583 nodes and 29,712 edges (Figure 3(A)). In addition, the PPI network of RDN-related genes was constructed with 2,950
Table 1: Bioactive compounds of *Rhizoma Dioscoreae* Nipponicae.

| Chemical          | Molecular formula | Molecular weight (g/mol) | OB (%) | DL | Compound 2D structure |
|-------------------|-------------------|--------------------------|--------|----|------------------------|
| 7-Epitaxol        | C_{47}H_{51}NO_{14} | 853.99                   | 45.18  | 0.24 | ![Structure of 7-Epitaxol](structure1.png) |
| Deoxyvasicinone   | C_{11}H_{10}N_{20} | 186.21                   | 56.29  | 0.1  | ![Structure of Deoxyvasicinone](structure2.png) |
| Diosgenin acetate | C_{29}H_{44}O_{4}  | 456.7                    | 16.72  | 0.72 | ![Structure of Diosgenin acetate](structure3.png) |
| Diosgenin, dehydro| C_{27}H_{40}O_{2}  | 396.6                    | 12.67  | 0.82 | ![Structure of Diosgenin, dehydro](structure4.png) |

Table 2: Targets of *Rhizoma Dioscoreae* Nipponicae.

| Gene symbol | Protein name                                               |
|-------------|------------------------------------------------------------|
| HTR4        | 5-hydroxytryptamine receptor 4                            |
| GABRA2      | Gamma-aminobutyric acid receptor subunit alpha-2           |
| PROS1       | Vitamin K-dependent protein S                              |
| PROZ        | Vitamin K-dependent protein Z                              |
| AVPR1A      | Vasopressin V1a receptor                                    |
| NQO2        | Ribosydihydronicotinamide dehydrogenase                     |
| HTR1B       | 5-hydroxytryptamine receptor 1B                            |
| GABRA3      | Gamma-aminobutyric acid receptor subunit alpha-3           |
| F7          | Coagulation factor VII                                      |
| F9          | Coagulation factor IX                                       |
| GGCX        | Vitamin K-dependent gamma-carboxylase                      |
| F10         | Coagulation factor X                                        |
| VKORC1      | Vitamin K epoxide reductase complex subunit 1              |
| JUN         | Transcription factor AP-1                                  |
| PROC        | Vitamin K-dependent protein C                              |
| OPRM1       | Mu-type opioid receptor                                     |
| AGTR2       | Type 2 angiotensin II receptor                              |
| BGLAP       | Osteocalcin                                                 |
| PTGS1       | Prostaglandin G/H synthase 1                                |
| AVPR2       | Vasopressin V2 receptor                                     |
| HTR1A       | 5-hydroxytryptamine receptor 1A                             |
| PTGS2       | Prostaglandin G/H synthase 2                                |
nodes and 65,942 edges (Figure 3(B)). These two networks were subsequently merged into an intersection with 681 nodes and 15,546 edges (Figure 3(C)). CytoNCA was used to assess the intersection of the PPI network by topological analysis. An RDN on asthma PPI network, with 151 nodes and 3,975 edges, was first screened based on the criteria of “BC ≥ 180333, CC ≥ 0.4842, and DC ≥ 52” (Figure 3(D)). A core-target PPI network was further screened using the criteria “BC ≥ 179866, CC ≥ 0.5113, and DC ≥ 7,” and consisted of 76 nodes and 1,587 edges (Figure 3(E)).

3.5. GO Functional Enrichment and Pathway Analysis. GO annotation showed that the targets of the PPI network were classified into 191 BP terms, 49 CC terms, and 68 MF terms according to \( p < 0.01 \). KEGG pathway analysis revealed that the targets of the PPI network were assigned to 43 KEGG pathways based on \( p < 0.01 \).

In the BP ontology, the targets of the PPI network were primarily associated with telomere organization, DNA replication-dependent nucleosome assembly, chromatin silencing at rDNA, protein heterotetramerization, negative regulation of gene expression, epigenetics, beta-catenin-TCF complex assembly, positive regulation of gene expression, cellular protein metabolic processes, nucleosome assembly, and gene silencing by RNA (Figure 4(a)).

For the CC ontology, the targets were located mainly in the protein complex, nuclear chromosome, telomeric region, nucleoplasm, nucleosome, cell-cell adherens junction, nucleus, membrane, extracellular matrix, and extracellular exosome (Figure 4(b)).

Based on GO annotation of MF, it was observed that the targets were mainly involved in nucleosomal DNA binding, histone binding, protein domain-specific binding, cadherin binding involved in cell-cell adhesion, protein heterodimerization activity, transcription factor binding, enzyme binding, ubiquitin-protein ligase binding, poly(A) RNA binding, and protein binding (Figure 4(c)).

In addition to functional GO annotation, KEGG pathway analysis was also conducted on the targets of the PPI network. As shown in Figure 4(d), KEGG pathway enrichment analysis suggested that the targets were mainly related to signaling pathways, such as systemic lupus erythematosus, alcoholism, viral carcinogenesis, cell cycle, prostate cancer, transcriptional misregulation in cancer, the thyroid hormone signaling pathway, hepatitis B, the PI3K-Akt signaling pathway, and pathways in cancer. The distribution of the key targets in systemic lupus erythematosus,
alcoholism, and viral carcinogenesis pathways is shown in Figure 5. The results indicated that the action targets of the main bioactive components of RDN were distributed in different metabolic pathways. The “multicomponents, multitargets, and multi-pathways” mutual regulation is a possible mechanism in the treatment of asthma.

3.6. Enrichment Analysis of the Hub Genes. Based on the core-target PPI network, hub genes were selected using Cyto-Hubba. The results showed that EZH2, SIRT1, CDK1, CUL7, NTRK1, MAPK1, RACK1, PARP1, CDK2, and BRCA1 were the top 10 hub nodes in the core-target PPI network. The PPI network of the hub genes is shown in Figure 6.

3.7. Molecular Docking Verification. The molecular docking assay was used to verify the binding ability of the bioactive components of RDN (detailed information regarding the bioactive components is listed in Table 5) and the top nine hub genes (CDK2, PDB: 1b39; SIRT1, PDB: 4jt8; RACK1, PDB: 4u66; EZH2, PDB: 5ij8; NTRK1, PDB: 5wr7; MAPK1, PDB: 6g54; CDK1, PDB: 6gu7; CUL7, PDB: 6o60; and PARP1, PDB: 7kkq). As shown in Table 6, we obtained 32
pairs of docking results when setting the threshold affinity to $< -5$ kcal/mol. Among them, diosgenin, dehydro had a strong binding ability with CDK1 (affinity $= -10.2$ kcal/mol), RACK1 (affinity $= -9.3$ kcal/mol), and SIRT1 (affinity $= -8.3$ kcal/mol). Additionally, 7-epitaxol had a strong binding ability with RACK1 (affinity $= -9.3$ kcal/mol) and CUL7 (affinity $= -9.1$ kcal/mol). Diosgenin acetate had a strong binding ability with SIRT1 (affinity $= -9.1$ kcal/mol), CDK2 (affinity $= -9$ kcal/mol), RACK1 (affinity $= -8.5$ kcal/mol), and CUL7 (affinity $= -8.4$ kcal/mol). Deoxyvasicinone had a strong binding ability with NTRK1 (affinity $= -8.4$ kcal/mol) (Figure 7).
3.8. Verification with Animal Experimentation. To further verify the therapeutic effect of RDN on asthma, we created a mouse model of ovalbumin-induced asthma. H&E staining results showed that the alveoli of mice in the control group had clear texture, no obvious inflammatory cell infiltration, regular bronchial lumen, no obvious thickening, intact airway mucosal epithelial cells, and an intact alveolar wall structure. The lung tissues of mice in the model and model + AKT agonist groups showed clear alveolar texture, a small amount of inflammatory cell infiltration, regular bronchial lumen, no obvious thickening, intact airway mucosal epithelial cells, and an intact alveolar wall structure. The lung tissues of mice in the model and model + AKT agonist groups showed clear alveolar texture, a small amount of inflammatory cell infiltration, regular bronchial lumen, no obvious thickening, intact airway mucosal epithelial cells, and an intact alveolar wall structure. The lung tissues of mice in the model and model + AKT agonist groups showed clear alveolar texture, a small amount of inflammatory cell infiltration, regular bronchial lumen, no obvious thickening, intact airway mucosal epithelial cells, and an intact alveolar wall structure. The lung tissues of mice in the model and model + AKT agonist groups showed clear alveolar texture, a small amount of inflammatory cell infiltration, regular bronchial lumen, no obvious thickening, intact airway mucosal epithelial cells, and an intact alveolar wall structure. The lung tissues of mice in the model and model + AKT agonist groups showed clear alveolar texture, a small amount of inflammatory cell infiltration, regular bronchial lumen, no obvious thickening, intact airway mucosal epithelial cells, and an intact alveolar wall structure. The lung tissues of mice in the model and model + AKT agonist groups showed clear alveolar texture, a small amount of inflammatory cell infiltration, regular bronchial lumen, no obvious thickening, intact airway mucosal epithelial cells, and an intact alveolar wall structure.

| Gene symbol | Gene description |
|-------------|------------------|
| SYK         | Tyrosine-protein kinase SYK |
| MAPK14      | Mitogen-activated protein kinase 14 |
| AIMP2       | Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 |
| SERPINE1    | Plasminogen activator inhibitor 1 |
| IL13        | Interleukin-13 receptor subunit alpha-2 |
| POLDIP2     | Polymerase delta-interacting protein 2 |
| RAG1        | V(D)J recombination-activating protein 1 |
| COL9A3      | Collagen alpha-3(IX) chain |
| COL9A1      | Collagen alpha-1(IX) chain |
| CTNNB1      | Catenin beta-1 |
| SCN8A       | Sodium channel protein type 8 subunit alpha |
| MAPK1       | Mitogen-activated protein kinase 1 |
| TGFBI       | Transforming growth factor beta-2 proprotein |
| CRK         | Adapter molecule crk |
| ACTB        | Actin, cytoplasmic 1 |
| ANXA2       | Annexin A2 |
| LGALS9      | Galectin-9 |
| COMP        | Cartilage oligomeric matrix protein |
| CSYSLR1     | Cysteinyl leukotriene receptor 1 |
| MMP9        | Matrix metalloproteinase-9 |
| COL9A2      | Collagen alpha-2(IX) chain |
| EGFR        | Epidermal growth factor receptor |
| GRAP2       | GRB2-related adapter protein 2 |
| SEMA7A      | Semaphorin-7A |
| MPPE1       | Metallophosphoesterase |
| AHSA1       | Activator of 90 kDa heat shock protein ATPase homolog 1 |
| TLR6        | Toll-like receptor 6 |
| RNFI9A      | E3 ubiquitin-protein ligase RNFI9A |
| TRPV4       | Transient receptor potential cation channel subfamily V member 4 |
| PELF        | Pulmonary function |
| SSRP1       | FACT complex subunit SSRP1 |
| LCN2        | Neutrophil gelatinase-associated lipocalin |
| TRPV1       | Transient receptor potential cation channel subfamily V member 1 |
| PDCD5       | Programmed cell death protein 5 |
| HMGB1       | High mobility group protein B1 |
| TACR1       | Substance-P receptor |
| ALOX5       | Polyunsaturated fatty acid 5-lipoxygenase |
| CCL11       | Eotaxin |
| TNF         | Tumor necrosis factor |
| ADRB2       | Beta-2 adrenergic receptor |
| MUC7        | Mucin-7 |
| HNMT        | Histamine N-methyltransferase |
| SGCB3A2     | Secretogoblin family 3A member 2 |
| PLA2G7      | Platelet-activating factor acetylhydrolase |
| BRCA2       | Breast cancer type 2 susceptibility protein |
| MIR126      | miRNA-126 |
| MIR148A     | miRNA-148A |
| MIR148B     | miRNA-148B |
| MIR152      | miRNA-152 |
| HLA-G       | HLA class I histocompatibility antigen |
| ASRT3       | Asthma-related traits, susceptibility to, 3 |
| ASRT4       | Asthma-related traits, susceptibility to, 4 |
| ASRT8       | Asthma-related traits, susceptibility to, 8 |
| ASRT6       | Asthma-related traits, susceptibility to, 6 |
bronchial lumen, and an intact airway mucosal epithelium; the damage to the lung tissue in the model + AKT agonist + RDN group was significantly reduced compared with that observed in the model group, and the inflammatory cell infiltration around the bronchi was reduced, but still heavier than that observed in the model + PA and model + RDN groups (Figure 8(a)).

We also detected the expression levels of the predicted targets and the PI3K-AKT pathway using qRT-PCR and Western blot analysis. As shown in Figure 8(b), compared with the control group, the expression of SIRT1 and MAPK1 was significantly decreased, while CDK2 expression significantly increased in the model + AKT agonist groups. This phenomenon was reversed by RDN administration. In addition, the expression of RACK1 and NTRK1 was significantly upregulated in the other groups compared with that in the control group, with no significant differences between the other groups. Furthermore, PI3K and AKT expression was not significantly different between the groups.

Western blotting showed that the expression of PARP1, EZH2, p-PI3K, and p-AKT was significantly increased in the model and model + AKT agonist groups compared with that in the control group, in contrast to the significantly decreased expression of MAPK1 and SIRT1. However, this inhibition or enhancement was reversed by the administration of RDN (Figure 8(c)).

4. Discussion

Asthma is a common, complex respiratory disease with high morbidity and mortality rates. RDN has been demonstrated to have an effect on asthma, but its pharmacological mechanisms have not been elucidated systematically and comprehensively. In this study, through network pharmacology, we further explored the mechanisms of RDN in asthma. Three aspects of our observations gained our attention. First, four bioactive compounds of RDN were identified. Second, systemic lupus erythematosus, alcoholism, viral carcinogenesis, cell cycle, and prostate cancer were
Figure 4: Gene ontology and KEGG pathway enrichment analysis of the core targets for Rhizoma Dioscoreae Nipponicae against asthma. (a) Representative bubble plots of the biological processes (BP) of the core targets. (b) Representative bubble plots of the cellular components (CC) of the core targets. (c) Representative bubble plots of the molecular function (MF) of the core targets. (d) Representative bubble plots of the KEGG pathway of the core targets. Gene ratio = count/set size.

classified as the key sections of RDN in asthma treatment at the gene level. Third, ten hub targets for asthma were enriched in pathological changes in airway inflammation and remodeling as well as other diseases.

In this study, we analyzed the targets of RDN and identified potential signaling pathways. There were a total of four bioactive components in the RDN with the standard. The main bioactive components of RDN are 7-epitaxol and deoxysyvacinone. The bioactive component-target network showed that these compounds had multiple targets. 7-Epitaxol (OB = 45.18, DL = 0.24) is a metabolite of taxol and has the same activity as taxol [36, 37]. Taxol has been reported to have a good clinical effect on asthma [38, 39]. Deoxysyvacinone (OB = 56.29, DL = 0.1) consists of a quinazolinoine moiety conjugated with pyrrolidine, a naturally occurring alkaloid with antibacterial, anti-inflammatory, and anti-proliferative activities [40, 41]. Moreover, HPLC analysis showed that diosgenin is an important component of RDN.

The results of GO enrichment analysis showed that all targets in the PPI network were mainly involved in beta-catenin-TCF complex assembly and other biological processes. An increasing body of evidence suggests that beta-catenin-TCF plays a key role in asthma. Beta-catenin-TCF is a pleiotropic cytokine involved in airway inflammatory responses and fibrotic tissue remodeling in the pathogenesis of asthma [42, 43].

KEGG pathway enrichment analysis showed enrichment in systemic lupus erythematosus, alcoholism, the PI3K-AKT signaling pathway, and other signaling pathways. A link between asthma and systemic lupus erythematosus (SLE) has been reported [44]. Charoenngam et al. found a significant association between asthma and an increased risk of SLE using a meta-analysis technique [45]. Collectively, alcoholism induces airway mast cells to release histamine, which exacerbates asthma in susceptible populations [46]. The PI3K-Akt pathway is thought to be closely associated with airway
**FIGURE 5:** Continued.

- **ALCOHOLISM**
- **Dopaminergic synapses**
- **Conclusions**

(a) Diagram showing various interactions and pathways related to alcoholism and dopaminergic synapses.

(b) Diagram illustrating the effects of acute and chronic ethanol on VTA GABA neuron excitability and DA release.

- **Acute ethanol**
  - Decrease in VTA GABA neuron excitability
  - Increase in DA neural activity

- **Chronic ethanol**
  - Increase in VTA GABA neuron excitability
  - Decrease in DA neural activity

- **GABAergic input**
  - Neuron (postsynaptic terminal)
  - DA release

- **DA synthesis and degradation**
  - Dopamine (DA)
  - Thio-dopa (TH AADC)
  - L-DOPA
  - MAO
  - DOPAC
  - H2O2

- **Synaptic input**
  - Glutamate input
  - GABAergic input

- **Ethanol (EtOH)**
  - Increased CREB function
  - Decreased ethanol intake

- **MAPK signaling pathway**
  - Angiogenesis
  - Immune evasion
  - Myeloid cell activation

- **Cell cycle progression**
  - p53 signaling
  - MAPK signaling
  - PI3K-Akt signaling

- **Apoptosis**
  - Inhibition of apoptosis
  - Activation of RAR
  - Proliferation
  - Survival

- **Transcription factors**
  - CREB
  - p53
  - Bcl-2

- **Epigenetic modifications**
  - DNA methylation
  - Histone modifications

- **Ventral tegmental area (VTA)**
  - Neuron (postsynaptic terminal)
  - DA release

- **Output**
  - Neuronal signaling
  - Neurotransmitter release

- **Conclusions**
  - Adaptative downregulation of PKA signaling
  - Alcohol reward mechanisms, excessive alcohol drinking behaviors

- **Kaposi sarcoma associated herpesvirus (KSHV)**
  - Immunoresponse
  - Immortalization
  - Transformation
  - Suppression of differentiation
  - Increased proliferation
d
Figure 5: Distribution of key targets in the most enriched pathways. (a) Distribution of key targets in viral carcinogenesis. (b) Distribution of key targets in alcoholism. (c) Distribution of key targets in systemic lupus erythematosus. The green rectangle represents the key targets.

Figure 6: The top 10 hub genes network of Rhizoma Dioscoreae Nipponicae against asthma.

Table 5: Chemical structure of active compounds.

| Synonyms   | CAS    | Molecular formula | 2D structure |
|------------|--------|-------------------|--------------|
| 7-Epitaxol | 105454-04-4 | C_{47}H_{51}NO_{14} | ![2D structure image] |
### Table 5: Continued.

| Synonyms                  | CAS    | Molecular formula | 2D structure |
|---------------------------|--------|-------------------|--------------|
| Deoxyvasicinone           | 530-53-0 | C_{11}H_{10}N_{20} | ![Image](image1.png) |
| Diosgenin acetate         | 1061-54-7 | C_{29}H_{44}O_{4} | ![Image](image2.png) |
| Diosgenin, dehydro        | 1672-65-7 | C_{37}H_{40}O_{2} | ![Image](image3.png) |

### Table 6: Results of molecular docking.

| Chemical                  | PDB    | Gene    | Best affinity |
|---------------------------|--------|---------|---------------|
| Diosgenin, dehydro        | 6gu7   | CDK1    | −10.2         |
| 7-Epitaxol                | 4u6r   | RACK1   | −9.3          |
| Diosgenin, dehydro        | 4u6r   | RACK1   | −9.3          |
| 7-Epitaxol                | 6o60   | CUL7    | −9.1          |
| Diosgenin acetate         | 4jt8   | SIRT1   | −9.1          |
| Diosgenin acetate         | 1b39   | CDK2    | −9            |
| Diosgenin acetate         | 4u6r   | RACK1   | −8.5          |
| Deoxyvasicinone           | 5wr7   | NTRK1   | −8.4          |
| Diosgenin acetate         | 6o60   | CUL7    | −8.4          |
| Diosgenin, dehydro        | 4jt8   | SIRT1   | −8.3          |
| Diosgenin, dehydro        | 1b39   | CDK2    | −8.3          |
| Diosgenin, dehydro        | 6o60   | CUL7    | −8.3          |
| Deoxyvasicinone           | 4jt8   | SIRT1   | −8            |
| Diosgenin acetate         | 6gu7   | CDK1    | −7.9          |
| Deoxyvasicinone           | 7kkq   | PARP1   | −7.7          |
| Diosgenin acetate         | 7kkq   | PARP1   | −7.7          |
| Diosgenin, dehydro        | 5ij8   | EZH2    | −7.6          |
| Diosgenin acetate         | 5ij8   | EZH2    | −7.5          |
| Diosgenin, dehydro        | 7kkq   | PARP1   | −7.4          |
| Diosgenin, dehydro        | 6g54   | MAPK1   | −7.3          |
| Deoxyvasicinone           | 6gu7   | CDK1    | −7.2          |
| Deoxyvasicinone           | 1b39   | CDK2    | −7.2          |
| Deoxyvasicinone           | 5ij8   | EZH2    | −7.2          |
| Deoxyvasicinone           | 4u6r   | RACK1   | −7            |
| Diosgenin, dehydro        | 5wr7   | NTRK1   | −6.9          |
| Diosgenin acetate         | 5wr7   | NTRK1   | −6.7          |
| 7-Epitaxol                | 6g54   | MAPK1   | −6.4          |
| Deoxyvasicinone           | 6g54   | MAPK1   | −6.4          |
| Deoxyvasicinone           | 6o60   | CUL7    | −6.3          |
| Diosgenin acetate         | 6g54   | MAPK1   | −6.3          |
| 7-Epitaxol                | 4jt8   | SIRT1   | −5.7          |
| 7-Epitaxol                | 5ij8   | EZH2    | −5            |
inflammation and is regulated by various upstream proteins. Azithromycin has been reported to affect airway remodeling in asthma via the PI3K/Akt pathway [47]. Brg1 exacerbates asthma airway inflammation by inhibiting the PI3K/Akt/mTOR pathway [48]. In addition, lncRNA-CASC7 enhances corticosteroid sensitivity by inhibiting the PI3K/AKT signaling pathway by targeting miR-21 in asthma [49].

In this study, 10 hub targets of RDN were identified for asthma treatment, and RACK1 and SIRT1 were shown to play important roles in asthma. The receptor for activated

![Figure 7: Molecular docking of bioactive compound hub genes. (a) Diosgenin, dehydro to CDK1, affinity = -10.2 kcal/mol. (b) 7-Epitaxol to RACK1, affinity = -9.3 kcal/mol. (c) Diosgenin, dehydro to RACK1, affinity = -9.3 kcal/mol. (d) 7-Epitaxol to CUL7, affinity = -9.1 kcal/mol. (e) Diosgenin acetate to SIRT1, affinity = -9.1 kcal/mol. (f) Diosgenin acetate to CDK2, affinity = -9 kcal/mol. (g) Diosgenin acetate to RACK1, affinity = -8.5 kcal/mol. (h) Deoxyvasicinone to NTRK1, affinity = -8.4 kcal/mol. (i) Diosgenin acetate to CUL7, affinity = -8.4 kcal/mol. (j) Diosgenin, dehydro to SIRT1, affinity = -8.3 kcal/mol.](image-url)
protein kinase C1 (RACK1), a component of the ribosome, located in the basal airway epithelium [50], plays an important role in a variety of biological responses, including cell growth, differentiation, and migration. Apoptosis and epithelial-mesenchymal transition (EMT) are two key components in the pathogenesis of asthma, both of which are mediated by TGF-β1. Knockdown of RACK1 significantly inhibited apoptosis and reduced TGF-β1 upregulation of EMT-related protein levels (N-calmodulin and Snail) in vitro [51]. Sirtuin 1 (SIRT1) is a class III histone deacetylase that plays an important role in the regulation of many pathophysiological processes, such as inflammation, autoimmunity, and apoptosis [52]. Lai et al. found that myeloid-specific SIRT1 deficiency exacerbated the airway inflammatory response in a mouse model of allergic asthma [53], which also suggests an important role for SIRT1 gene activation in asthma treatment.

Finally, we validated the results of the network pharmacological approach using molecular docking and in vivo experiments in asthmatic mice. The molecular docking assay showed that the binding energy of the active compounds in RDN to the predicted targets was less than −5 kcal/mol, suggesting that RDN binds well to the therapeutic targets in asthma. In addition, Western blot results showed that RDN reduced the expression of p-P13K and p-AKT, suggesting that RDN resistance to asthma may be achieved through the PI3K-AKT pathway.

5. Conclusions

In summary, network pharmacology showed that the bioactive components of RDN, particularly 7-epitaxol and deoxyvasicinone, could act on multiple targets. RDN was effective in treating asthma mainly through the pathways related to systemic lupus erythematosus and alcoholism, the PI3K-AKT signaling pathway, and other signaling pathways. The results of molecular docking, qRT-PCR, and Western blot analysis suggest that PARP1, CDK2, and MAPK1 might play important roles in the treatment of asthma. This study provides a basis for the treatment of asthma by RDN from the perspective of network pharmacology. These findings have guiding significance for the clinical application of RDN and provide new clues for the future study and development of new drugs. Of course, our study also needs more in vitro
and in vivo experiments to verify the proposed molecular targets.

Data Availability
The raw data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This study was supported by the Zhejiang Provincial Department of Education (General Scientific Research Projects) (No. Y202045102) and the National Natural Science Foundation of China (Youth Foundation) (No. 81503522).

Supplementary Materials
Supplementary Figure 1. HPLCs. (A) Standard solution; (B) Rhizoma Dioscoreae Nipponicae sample solution. Supplementary Table 1. The primers used in the qRT-PCR analysis.

References
[1] National Asthma Education and Prevention Program, “National asthma education and prevention program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002,” The Journal of Allergy and Clinical Immunology, vol. 110, no. 5, pp. S141–S219, 2002.
[2] J. W. Mims, “Asthma: definitions and pathophysiology,” International Forum of Allergy & Rhinology, vol. 5, no. 1, pp. S2–S6, 2015.
[3] J. R. Castillo, S. P. Peters, and W. W. Busse, “Asthma exacerbations: pathogenesis, prevention, and treatment,” The Journal of Allergy and Clinical Immunology: In Practice, vol. 5, no. 4, pp. 918–927, 2017.
[4] C. Mattiuzzi and G. Lippi, “Worldwide asthma epidemiology: insights from the global health data database,” International Forum of Allergy & Rhinology, vol. 10, no. 1, pp. 75–80, 2020.
[5] J. Stern, J. Pier, and A. A. Litonjua, “Asthma epidemiology and risk factors,” Seminars in Immunopathology, vol. 42, no. 1, pp. 5–15, 2020.
[6] M. Liu, G. Y. Liu, S. Y. Hu, L. L. Wan, H. Y. Cai, and Y. L. Xu, “Treatment of mild-to-moderate bronchial asthma (heat wheezing syndrome) patients at acute onset with western medicine combined danlong oral liquid: a multi-center, randomized double-blinded, positive-controlled clinical trial,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 35, no. 5, pp. 529–533, 2015.
[7] H. P. Zhang, L. Wang, Z. Wang et al., “Chinese herbal medicine formula for acute asthma: a multi-center, randomized, double-blind, proof-of-concept trial,” Respiratory Medicine, vol. 140, pp. 42–49, 2018.
[8] L. Wang, X. Zheng, Y. Hui et al., “Adjuvant treatment with Xiaoqinglong formula for bronchial asthma: protocol of systematic review and meta-analysis,” Medicine, vol. 98, no. 35, Article ID e17053, 2019.
[9] B. F. Asher, M. D. Seidman, W. D. Reddy, and F. S. Omore, “Integrative medical approaches to allergic rhinitis,” Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 23, no. 3, pp. 221–225, 2015.
[10] W. C. Chou, H. J. Liu, Y. W. Lin et al., “2 Hz electro-acupuncture at yiningquan (SP9) and ququan (LR8) acupoints induces changes in blood flow in the liver and spleen,” The American Journal of Chinese Medicine, vol. 40, no. 1, pp. 75–84, 2012.
[11] Y. Guo, E. Xing, X. Liang, H. Song, and W. Dong, “Effects of total saponins from rhizoma dioscoreae nipponicae on expression of vascular endothelial growth factor and angio-poietin-2 and Tie-2 receptors in the synovium of rats with rheumatoid arthritis,” Journal of the Chinese Medical Association, vol. 79, no. 5, pp. 264–271, 2016.
[12] Q. Zhou, D. H. Yu, S. M. Liu, and Y. Liu, “Total saponins from discorea nipponica makino ameliorate urate excretion in hyperuricemic rats,” Pharmacognosy Magazine, vol. 11, no. 43, pp. 567–573, 2015.
[13] Y. Cao, J. Li, and J. Liu, “A study of the impact of dioscorea nipponica on the level of serum TSH, TGA and TPO-Ab of hashimoto’s thyroiditis patient,” Chinese General Practice, vol. 16, no. 27, pp. 2486–2488, 2013.
[14] J. Yang, S. Cao, and W. Gu, “Relieving effect of total saponins from rhizoma dioscorea nipponica on bleomycin-induced pulmonary fibrosis by regulating TGF-β1/α-SMA pathway in rats,” Chinese Pharmacist, vol. 23, no. 10, pp. 1905–1910, 2020.
[15] Y. Ye, K. Song, and L. Jiang, “Influence of con-saponin of dioscoreae nipponicae on interleukin-17A in chronic asthma mice,” Chinese Archives of Traditional Chinese Medicine, vol. 33, no. 1, pp. 168–171, 2015.
[16] L. Jiang and J. Dai, “Effects of con-saponin of dioscoreae nipponicae on BRP-39 expression and PI3K/AKT signal pathway in chronic asthmatic mice,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 40, no. 1, pp. 75–79, 2020.
[17] X. Cai, Z. Wang, and L. Jiang, “Effect of con-saponin of dioscoreae nipponicae on airway remodeling in asthmatic mice,” Journal of Zhejiang Chinese Medical University, vol. 37, no. 6, pp. 756–760, 2013.
[18] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Drug Targets, vol. 6, no. 1, p. 13, 2014.
[19] A. L. Hopkins, “Network pharmacology,” Nature Biotechnology, vol. 25, no. 10, pp. 1110–1111, 2007.
[20] S. Saikia and M. Bordoloi, “Molecular docking: challenges, Advances and its use in drug discovery perspective,” Current Drug Targets, vol. 20, no. 5, pp. 501–521, 2019.
[21] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.
[22] X. Xu, W. Zhang, C. Huang et al., “A novel chemometric method for the prediction of human oral bioavailability,” International Journal of Molecular Sciences, vol. 13, no. 6, pp. 6964–6982, 2012.
[23] W. P. Walters and M. A. Murcko, “Prediction of “drug likeness”,” Advanced Drug Delivery Reviews, vol. 54, no. 3, pp. 255–271, 2002.
[24] J. Huang, F. Cheung, H.-Y. Tan et al., “Identification of the active compounds and significant pathways of yinchenhao
decoction based on network pharmacology,” *Molecular Medicine Reports*, vol. 16, no. 4, pp. 4583–4592, 2017.

[25] T. Wang, R. C. Y. Choi, J. Li et al., “Trillin, a steroidal saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress,” *Journal of Ethnopharmacology*, vol. 139, no. 1, pp. 214–220, 2012.

[26] Z. Liu, F. Guo, Y. Wang et al., “BATMAN-TCM: a bioinformatics analysis tool for molecular mechAnism of traditional Chinese medicine,” *Scientific Reports*, vol. 6, no. 1, Article ID 21146, 2016.

[27] L. Breuza, S. Poux, A. Estreicher et al., “The UniProtKB guide to the human proteome,” *Database: The Journal of Biological Databases and Curation*, vol. 2016, 2016.

[28] G. Stelzer, N. Rosen, I. Plaschkes et al., “The Genecards suite: from gene data mining to disease genome sequence analyses,” *Current Protocols in Bioinformatics*, vol. 54, pp. 1–33, 2016.

[29] J. Piñero, J. M. Ramirez-Anguita, J. Saúch-Pitarch et al., “The DisGeNET knowledge platform for disease genomics: 2019 update,” *Nucleic Acids Research*, vol. 48, no. D1, pp. D845–D855, 2020.

[30] A. Martin, M. E. Ochagavia, L. C. Rabasa, J. Miranda, J. Fernandez-de-Cossio, and R. Bringas, “BisoGenet: a new tool for gene network building, visualization and analysis,” *BMC Bioinformatics*, vol. 11, no. 1, pp. 91, 2010.

[31] Y. Tang, M. Li, J. Wang, Y. Pan, and F.-X. Wu, “CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks,” *Biosystems*, vol. 127, pp. 67–72, 2015.

[32] C. H. Chin, S. H. Chen, H. H. Wu, C. W. Ho, M. T. Ko, and C. Y. Lin, “cytoHubba: identifying hub objects and sub-networks from complex interactome,” *BMC Systems Biology*, vol. 8, no. 4, p. S11, 2014.

[33] W. Yan, L. Ji, S. Hang, and Y. Shun, “New ionic liquid-based preparative method for diosgenin from Rhizoma dioscoreae nipponicae,” *Pharmaceuticals*, vol. 6, no. 3, pp. 250–254, 2013.

[34] T. Sterling and J. J. Irwin, “ZINC 15-ligand discovery for everyone,” *Journal of Chemical Information and Modeling*, vol. 55, no. 11, pp. 2324–2337, 2015.

[35] S. K. Burley, H. M. Berman, G. J. Kleywegt, J. L. Markley, H. Nakamura, and S. Venkata, “Protein Data Bank (PDB): the single global macromolecular structure Archive,” *Methods in Molecular Biology*, vol. 1607, pp. 627–641, 2017.

[36] Y. Liu, X. Ma, M. Zhou, X. Hao, and X. Zhu, “An effective method to produce 7-epitaxol from taxol in HCO3-,” *Bioorganic & Medicinal Chemistry Letters*, vol. 30, no. 15, Article ID 127285, 2020.

[37] M. Mariotti, R. Colognato, M. Rimoldi et al., “Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity,” *Anti-Cancer Agents in Medicinal Chemistry*, vol. 15, no. 3, pp. 400–405, 2015.

[38] N. Parinyanitikul, W. Tanpipattanakul, N. Poovorawan et al., “Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy,” *Supportive Care in Cancer*, vol. 26, no. 7, pp. 2471–2477, 2018.

[39] K. Nymberg, S. Folan, M. Berger et al., “Comparison of subsequent infusion hypersensitivity reactions to paclitaxel using two different infusion strategies,” *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, vol. 29, 2021.

[40] H.-J. Zhong, K.-H. Leung, S. Lin et al., “Discovery of deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme,” *Methods*, vol. 71, pp. 71–76, 2015.

[41] F. Ma and H. Du, “Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: design, synthesis, and biological evaluation,” *European Journal of Medicinal Chemistry*, vol. 140, pp. 118–127, 2017.

[42] R. Huo, X. Tian, Q. Chang, D. Liu, C. Wang, and J. Bai, “Targeted inhibition of β-catenin alleviates airway inflammation and remodeling in asthma via modulating the profibrotic and anti-inflammatory actions of transforming growth factor-β1,” *Therapeutic Advances in Respiratory Disease*, vol. 15, Article ID 175346620981858, 2021.

[43] M. Al-Alawi, T. Hassan, and S. H. Chotirmall, “Transforming growth factor β and severe asthma: a perfect storm,” *Respiratory Medicine*, vol. 108, no. 10, pp. 1409–1423, 2014.

[44] E. Sin, P. Anand, and M. Frieri, “A link: allergic rhinitis, asthma & systemic lupus erythematosus,” *Autoimmunity Reviews*, vol. 15, no. 5, pp. 487–491, 2016.

[45] N. Charoenngam, B. Ponvilawan, W. Wongtrakul, and P. Ungprasert, “Patients with asthma have a higher risk of systemic lupus erythematosus: a systematic review and meta-analysis,” *Clinical Rheumatology*, vol. 40, no. 2, pp. 529–536, 2021.

[46] H. Matsuse, “Mechanism and management of alcohol-induced asthma,” *Nihon Arukoru Yakubutsu Igakkai Zasshi*, vol. 51, no. 3, pp. 214–220, 2016.

[47] X. Zhao, F. Q. Yu, X. J. Huang et al., “Azithromycin influences airway remodeling in asthma via the PI3K/Akt/mTOR/HIF-1α/VEGF pathway,” *Journal of Biological Regulators and Homeostatic Agents*, vol. 32, no. 5, pp. 1679–1688, 2018.

[48] W. Zou, F. Ding, C. Niu, Z. Fu, and S. Liu, “Brg1 aggravates airway inflammation in asthma via inhibition of the PI3K/Akt/mTOR pathway,” *Biochemical and Biophysical Research Communications*, vol. 503, no. 4, pp. 3212–3218, 2018.

[49] R. E. Slager, J. M. Devasure, J. A. Pavlik, J. H. Sisson, and S. H. Chotirmall, “Transforming growth factor RI regulates the expression of αvβ6 integrin in inflammation and remodeling in asthma via the PI3K/Akt/mTOR/HIF-1α/VEGF pathway,” *Anti-Cancer Agents in Medicinal Chemistry*, vol. 26, no. 7, pp. 2471–2477, 2016.

[50] F. Ma and H. Du, “Novel deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme,” *Methods*, vol. 71, pp. 71–76, 2015.